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Abstract
Aim: To determine whether metformin's effects on carotid artery intima-media thick-
ness (cIMT) in type 1 diabetes differ according to smoking status.
Methods: Regression model effect estimates for the effect of metformin versus pla-
cebo (double-blind) on carotid IMT were calculated as a subgroup analysis of the
REMOVAL trial.
Results: In 428 randomized participants (227 never-smokers, 201 ever-smokers),
averaged mean carotid IMT progression (per year) was reduced by metformin versus
placebo in never-smokers (−0.012 mm, 95% CI −0.021 to −0.002; p = .0137) but not
in ever-smokers (0.003 mm, 95% CI −0.008 to 0.014; p = .5767); and similarly in non-
current smokers (−0.008 mm, 95% CI −0.015 to −0.00001; p = .0497) but not in
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current smokers (0.013 mm, 95% CI −0.007 to 0.032; p = .1887). Three-way interac-
tion terms (treatment*time*smoking status) were significant for never versus ever
smoking (p = .0373, prespecified) and non-current versus current smoking (p = .0496,
exploratory). Averaged maximal carotid IMT progression (per year) was reduced by
metformin versus placebo in never-smokers (−0.020 mm, 95% CI −0.034 to −0.006;
p = .0067) but not in ever-smokers (−0.006 mm, 95% CI −0.020 to 0.008; p = .4067),
although this analysis was not supported by a significant three-way interaction term.
Conclusions: This subgroup analysis of the REMOVAL trial provides additional sup-
port for a potentially wider role of adjunct metformin therapy in cardiovascular risk
management in type 1 diabetes, particularly for individuals who have never smoked
cigarettes.
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1 | INTRODUCTION
Although the prevalence of cigarette smoking has declined to around
15% of the general population in the UK and the United States, it
remains the most significant cause of preventable premature mortality
worldwide with an estimated 6 million deaths annually.1,2 The propor-
tion of people with type 1 diabetes reporting current smoking is at
least as high (15%-20%), or higher in some populations, while an addi-
tional 20%-25% are former smokers.3,4 As the commonest cause of
premature death in type 1 diabetes is cardiovascular disease (CVD)
and the detrimental effects of smoking on the vasculature are well
documented, this is an unfortunate combination.4–7 A meta analysis
has shown that smoking is associated with a 50% increase in the risk
of adverse cardiovascular outcomes in diabetes, although there are
few data specific to type 1 diabetes.4
In the REducing with MetfOrmin Vascular Adverse Lesions
(REMOVAL) trial (NCT01483560), a randomized, double-blind,
placebo-controlled trial of metformin adjunct therapy in high
cardiovascular-risk adults with type 1 diabetes, carotid intima-media
thickness (IMT) was measured annually over 3 years as a surrogate
marker of atherosclerosis progression strongly associated with CVD
outcomes.8,9 In the main analysis, progression of averaged mean far
wall carotid IMT (the primary outcome) did not differ significantly
between the metformin and placebo groups during follow-up. How-
ever, progression of averaged maximal far wall carotid IMT (a tertiary
outcome) was significantly reduced by metformin.9 Of note, the
Mannheim Consensus favours mean carotid IMT as an outcome mea-
sure for studies in the general population,10 but post-randomization
follow-up analyses of the Diabetes Control and Complications Trial
(DCCT) in type 1 diabetes reported maximal carotid IMT.11,12
Smoking is strongly associated with carotid IMT progression and
adverse cardiovascular outcomes in the general population.13 Its pro-
atherosclerotic effects are mediated by a variety of mechanisms
including release of pro-inflammatory cytokines, free radical forma-
tion, LDL oxidation, reduced bioavailability of nitric oxide, induction of
a pro-thrombotic state and monocyte adhesion to vascular cells.14–19
Smoking has been shown to interact with ageing and metabolic syn-
drome to accelerate carotid IMT progression. With the hypothesis
that powerful adverse effects of smoking may attenuate protective
vascular effects of metformin, we conducted a prespecified subgroup
analysis of the REMOVAL trial with the aim of determining whether
metformin's effects on carotid artery intima-media thickness in type
1 diabetes differ according to smoking status.
2 | METHODS
The REMOVAL trial was undertaken at 23 hospital diabetes clinics in
five different countries (UK, Canada, Australia, the Netherlands and
Denmark); 428 adults aged 40 years and older with type 1 diabetes of at
least 5 years’ duration and at least three of 10 specified risk factors for
CVD were randomized from December 2011 to June 2014 to either
metformin 1000 mg twice daily (or maximum dose tolerated) or placebo
in addition to usual insulin therapy and were followed up over 3 years.
The primary objective (reported elsewhere) was to investigate whether
adding metformin to standard titrated insulin therapy reduced progres-
sion of atherosclerosis as measured by carotid IMT at 12, 24 and
36 months.9 Cigarette smoking status was ascertained by self-report at
baseline (never, former or current; duration where applicable).
2.1 | Statistical analysis
The ‘ever’ smoking group consisted of those reporting ‘current’ or
‘former’ smoking (independent of duration) (Figure S1). ‘Never’ ver-
sus ‘ever’ smoking status was one of 11 subgroup analyses
prespecified in the statistical analysis plan for the primary carotid IMT
outcome; the others were age, sex, baseline carotid IMT, history of
CVD, duration of diabetes, baseline HbA1c, body mass index (BMI),
LDL-cholesterol, systolic blood pressure and insulin pump use.
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Baseline data in each of the groups according to smoking status were
summarized using means and standard deviations for continuous vari-
ables and by number and percentages for categorical variables. Three-
way interaction terms (treatment*time*subgroup) were calculated for
all prespecified subgroups (Table S1). Where appropriate, repeated-
measures random effects regression (as previously described for the
main analysis) was used to assess the effect of metformin within sub-
groups.9 Following review of carotid IMT results by ‘never’ versus
‘ever’ smoking status, the steering committee requested a further
exploratory analysis by ‘non-current’ versus ‘current’ smoking status.
As the ‘non-current’ smoking group consisted of ‘never’ and ‘former’
smokers combined (Figure S1), a further exploratory analysis was con-
ducted according to never versus former versus current smoking. Ana-
lyses were performed with SAS (version 9.3) with a two-sided
significance level of 5%. No adjustments for multiple comparisons
were prespecified.
3 | RESULTS
Of 428 randomized participants ([mean ± SD] age 55.5 ± 8.6 years,
HbA1c 8.1% ± 0.82% (64.5 ± 9.0 mmol/mol), BMI 28.5 ± 4.3 kg/m2,
duration of diabetes 34 ± 10.8 years), 227 (53%) were never-smokers
and 201 (47%) were ever-smokers. In further analyses, 371 (87%)
were non-current smokers and 57 (13%) were current smokers.
Smoking duration was 22.2 ± 13.2 years for ever-smokers and 31.6
± 12.4 years for current smokers. Other baseline demographic charac-
teristics by smoking status are shown in Table 1.
Carotid IMT was higher at baseline in ever-smokers versus never-
smokers (0.815 ± 0.157 vs. 0.752 ± 0.161 mm; p < .0001) but not in
current versus non-current smokers (0.801 ± 0.163 vs. 0.779 ±
0.162 mm; p = .3283).
The three-way (treatment*time*subgroup) interaction term for
the prespecified subgroup analysis of the primary outcome (averaged
mean carotid IMT) for never versus ever smoking was significant
(p = .0373). Progression of averaged mean carotid IMT was reduced
by metformin in never-smokers (−0.012 mm per year, 95% CI −0.021
to −0.002; p = .0137) but not in ever-smokers (0.003 mm per year,
95% CI −0.008 to 0.014; p = .5767) (Figure 1). The three-way (tre-
atment*time*subgroup) interaction term was also significant in explor-
atory analysis of the same outcome by non-current versus current
smoking (p = .0496). Thus, averaged mean carotid IMT progression
was reduced in non-current smokers (−0.008 mm per year, 95% CI
−0.015 to −0.00001; p = .0497) but not in current smokers
(0.013 mm per year, 95% CI −0.007 to 0.032; p = .1887) (Figure 2).
The three-way (treatment*time*subgroup) interaction term for explor-
atory analysis according to never versus former versus current
smoking was supported by a borderline significant three-way
TABLE 1 Baseline characteristics of REMOVAL participants by smoking status
Lifetime smoking (n = 428) Current smoking (n = 428)
Never smoked (n = 227) Ever smokeda (n = 201) Non-smokerb (n = 371) Current smoker (n = 57)
Age (years) 54.9 (8.6) 56.2 (8.6) 55.8 (8.7) 53.5 (7.9)
Male (%) 127 (56) 126 (63) 215 (58) 38 (67)
Years of diabetes 33.9 (9.8) 33.7 (11.8) 34.4 (10.6) 29.9 (11.6)
Existing CVDc (%) 26 (11.5) 26 (12.9) 47 (12.7) 5 (8.8)
Averaged mean cIMT 0.752 (0.161) 0.815 (0.157) 0.779 (0.162) 0.801 (0.163)
Averaged maximal cIMT 0.883 (0.196) 0.958 (0.188) 0.915 (0.196) 0.938 (0196)
Years of smoking — 22.2 (13.2) 18.5 (11.6) 31.6 (12.4)
HbA1c (%) 8.0 (0.79) 8.1 (0.86) 8.0 (0.80) 8.2 (0.95)
HbA1c (mmol/mol) 64.3 (8.62) 64.6 (9.43) 64.3 (8.77) 65.7 (10.40)
BMI (kg/m2) 28.5 (4.0) 28.4 (4.7) 28.8 (4.3) 263 (3.5)
Systolic BP (mmHg) 129 (14.8) 131 (14.8) 130 (15.2) 126 (11.9)
Cholesterol 40 (0.87) 40 (0.95) 40 (0.91) 40 (0.87)
eGFR (mL/min/1.73m2) 92 (21.8) 92 (20.6) 92 (21.3) 91 (21.1)
BP-lowering treatment (Y/N) 162 (71) 151 (75) 273 (74) 40 (70)
Statin treatment (Y/N) 186 (82) 163 (81) 305 (82) 44 (77)
Aspirin treatment (Y/N) 79 (35) 72 (36) 129 (35) 22 (39)
Clopidogrel treatment (Y/N) 9 (4) 7 (4) 16 (4) 0 (0)
Abbreviations: BMI, body mass index; BP, blood pressure; cIMT, carotid intima-media thickness; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate.
Mean (SD) or number (%).
aFormer smokers and current smokers combined.
bNever-smokers and ex-smokers combined (see Figure S1).
cIncludes heart failure, coronary artery bypass graft, stent, angina, transient ischaemic attack, peripheral vascular disease.
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interaction term (p = .0544). There was no attenuation of carotid IMT
progression with metformin versus placebo in former smokers
(n = 144; p = .9185) (Figure S2).
Progression of the tertiary carotid outcome, averaged maximal
carotid IMT, was also reduced by metformin in never-smokers
(−0.020 mm per year, 95% CI −0.034 to −0.006; p = .0067) but not in
ever-smokers (−0.006 mm per year, 95% CI −0.020 to 0.008;
p = .4067), and in non-current (−0.014 mm per year, 95% CI −0.025
to −0.003; p = .0102) but not in current (−0.006 mm per year, 95% CI
−0.032 to 0.020; p = .6543) smokers (data not shown). These analyses
were not supported by statistically significant interaction terms
(p = .1764 and p = .5280, respectively).
Three-way (treatment*time*subgroup) interaction terms for the
other 10 prespecified subgroup analyses, including sex, were not sta-
tistically significant for the primary outcome (Table S1). As 97% of
participants self-reported as White, a subgroup analysis by ethnicity
could not be performed.
4 | DISCUSSION
While subgroup analyses must be interpreted with caution, in a
prespecified analysis of the REMOVAL trial, we observed that the
effect of metformin on carotid IMT in type 1 diabetes differed
according to smoking status. In individuals who had never smoked,
treatment with metformin for 3 years attenuated progression of
this well-validated surrogate measure of CVD9 despite an average
duration of diabetes—in the majority of cases with associated
hypertension and dyslipidaemia—of more than 30 years. This was
broadly consistent whether carotid IMT was measured as
averaged mean (primary outcome) or averaged maximal (tertiary
outcome).
REMOVAL is the largest trial examining the role of metformin in
type 1 diabetes.9 Carotid IMT was selected as a surrogate vascular
outcome because it is a well-validated, non-invasive marker of CVD
that predicts clinical events in the general population8,13,20; indeed,
since REMOVAL was completed and the main results were published,
a large and robust meta-analysis has shown that the extent to which
an intervention reduces progression of mean carotid IMT is closely
associated with the degree of CVD reduction observed.8 Mean far
wall carotid IMT is a measurement of IMT over 10-mm arterial seg-
ments proximal to the carotid bifurcation (in three planes for each
artery). In REMOVAL, following the Mannheim Consensus, individual
carotid IMT measurements greater than 1.5 mm—potentially indica-
tive of atherosclerotic plaque—were excluded from the primary out-
come analysis. Maximal carotid IMT is the mean of the maximum IMT
measured in each of these carotid segments that is inclusive of areas
of plaque.20 The main trial results showed that metformin reduced
F IGURE 2 Primary carotid
outcome (averaged mean carotid IMT)
by current smoking status. In non-
current smokers [left panel, n = 371],
progression of averaged mean carotid
IMT by repeated-measures regression
was reduced by metformin (p = .0497).
In current smokers (right panel, n = 57)
there was no effect of metformin
(p = .1887). Error bars represent 95%
confidence intervals
F IGURE 1 Primary carotid
outcome (averaged mean carotid IMT)
by lifetime smoking status. In never
smokers [left panel, n = 227]
progression of averaged mean carotid
IMT by repeated-measures regression
was reduced by metformin (red) vs.
placebo (blue) (p = .0137). In ever
smokers [right panel, n = 201] there
was no effect of metformin (p= .5767).
Error bars represent 95% confidence
intervals
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averaged maximal carotid IMT (tertiary outcome) but not averaged
mean carotid IMT (primary outcome).9,21 In revealing an interaction
with smoking status, and that progression of both carotid IMT out-
comes was significantly reduced by metformin in never-smokers, the
present subgroup analyses provide important and potentially clinically
significant insights into the previously reported findings.9
Of note, two previous trials that examined the effect of
metformin on carotid IMT in other populations reported no
effect.22,23 However, both were smaller than REMOVAL and had
half the duration of follow-up: indeed, the latter acknowledged a
lack of statistical power. No previous studies have examined
the impact of metformin by smoking status on either surrogate or
clinical cardiovascular outcomes in type 1 diabetes. One large observa-
tional cohort study in type 2 diabetes concluded that metformin has
a protective effect against CVD specifically in smokers. However,
this was a non-randomized study, in which only 17% of smokers were
taking metformin therapy and demographic information was not pres-
ented by metformin treatment status. While findings in type 2 diabetes
cannot be directly extrapolated to type 1 diabetes, it seems possible
using this design that metformin operated as a marker of absence of
co-morbidity, that is, there may have been residual confounding by
indication.24
Smoking rates are decreasing globally but many people with type
1 diabetes continue to smoke.1,2,4,25 Smoking, diabetes and hyperten-
sion are all major contributors to increased carotid IMT and the devel-
opment and progression of atherosclerotic plaque.17–19,25,26 The
mechanisms involved are complex15 but include induction of pro-
inflammatory cytokines and recruitment of leukocytes to the vascular
wall.4,15 In type 1 diabetes, dysglycaemia (including both hyper- and
hypoglycaemia) additionally acts to increase vascular inflammation,
promote thrombosis, increase deleterious lipids and impair nitric oxide
availability.4,27
A variety of lines of evidence exist to support an antia-
therosclerotic effect of metformin and a reduced risk of adverse car-
diovascular outcomes, mainly in type 2 diabetes.28,29 The principal
mechanisms invoked include inhibition of vascular pro-inflammatory
pathways30–34 and reduction of differentiation of monocytes to mac-
rophages at the endothelial level (thereby inhibiting foam cell forma-
tion).32,33 Reduction in HbA1c with metformin in the REMOVAL trial
was only statistically but not clinically significant, hence effects on
carotid IMT progression were most probably glycaemia independent.9
To account for our findings in the present analysis we speculate that
metformin was unable to mitigate the multiple deleterious vascular
mechanisms in play at the vascular wall in individuals who had a his-
tory of many decades of both type 1 diabetes and cigarette smoking.
Studies in murine models suggest that metformin may prevent early
atherogenesis but not reverse more established disease33: by analogy,
cigarette-smoking participants in REMOVAL may have had more
established atherosclerotic plaques that were less susceptible to
metformin's vascular effects.
Against this conjecture, other agents that reduce vascular risk in
type 1 diabetes (e.g. antihypertensives, statins) have not been shown to
be less effective in smokers. It could also be argued that higher baseline
carotid IMT should have provided greater scope for a metformin-
related reduction over time to be shown (although such a reduction
may have been more difficult to detect because of greater measure-
ment variability). Alternatively, there may have been unmeasured
behavioural or other differences according to smoking status to account
for the observed differences in carotid IMT progression between
groups, for example, other health behaviours or lower adherence to
prescribed therapies.
The strengths of this analysis are the evaluation of well-
characterized adults with type 1 diabetes in the setting of a rigorous
placebo-controlled randomized trial with prestated hypotheses. Sub-
group analysis by smoking status was supported by significant interac-
tion terms, although as for other subgroups prespecified in the
statistical analysis plan, these were not adjusted for multiple compari-
sons. Other limitations relate to use of a surrogate outcome for CVD,
self-reporting of smoking status and the lack of ongoing data on
smoking exposure during the trial.
In conclusion, the present subgroup analysis of the REMOVAL
trial provides further support for a potentially wider role of adjunct
metformin therapy in cardiovascular risk reduction in type 1 diabetes,
particularly for individuals who have never smoked cigarettes. Cardio-
vascular outcome trials are required to elucidate whether metformin
(or other adjunct agents) may offer cardiovascular risk reduction in
this high-risk population.
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